Eupraxia Pharmaceuticals (EPRX) Competitors $5.36 -0.04 (-0.74%) Closing price 03:54 PM EasternExtended Trading$5.60 +0.24 (+4.48%) As of 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EPRX vs. NAGE, DAWN, VIR, ABUS, VALN, TNGX, BGM, KURA, GHRS, and NRIXShould you be buying Eupraxia Pharmaceuticals stock or one of its competitors? The main competitors of Eupraxia Pharmaceuticals include Niagen Bioscience (NAGE), Day One Biopharmaceuticals (DAWN), Vir Biotechnology (VIR), Arbutus Biopharma (ABUS), Valneva (VALN), Tango Therapeutics (TNGX), BGM Group (BGM), Kura Oncology (KURA), GH Research (GHRS), and Nurix Therapeutics (NRIX). These companies are all part of the "pharmaceutical products" industry. Eupraxia Pharmaceuticals vs. Its Competitors Niagen Bioscience Day One Biopharmaceuticals Vir Biotechnology Arbutus Biopharma Valneva Tango Therapeutics BGM Group Kura Oncology GH Research Nurix Therapeutics Niagen Bioscience (NASDAQ:NAGE) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends. Which has more risk & volatility, NAGE or EPRX? Niagen Bioscience has a beta of 2.21, suggesting that its stock price is 121% more volatile than the S&P 500. Comparatively, Eupraxia Pharmaceuticals has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500. Which has stronger valuation & earnings, NAGE or EPRX? Niagen Bioscience has higher revenue and earnings than Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNiagen Bioscience$99.60M7.46$8.55M$0.2144.38Eupraxia PharmaceuticalsN/AN/A-$25.50M-$0.85-6.31 Do analysts rate NAGE or EPRX? Niagen Bioscience currently has a consensus price target of $13.42, indicating a potential upside of 43.99%. Eupraxia Pharmaceuticals has a consensus price target of $11.00, indicating a potential upside of 105.22%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eupraxia Pharmaceuticals is more favorable than Niagen Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Niagen Bioscience 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Eupraxia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Does the media prefer NAGE or EPRX? In the previous week, Niagen Bioscience had 1 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 3 mentions for Niagen Bioscience and 2 mentions for Eupraxia Pharmaceuticals. Niagen Bioscience's average media sentiment score of 0.46 beat Eupraxia Pharmaceuticals' score of 0.34 indicating that Niagen Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Niagen Bioscience 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Eupraxia Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders believe in NAGE or EPRX? 15.4% of Niagen Bioscience shares are held by institutional investors. 9.4% of Niagen Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is NAGE or EPRX more profitable? Niagen Bioscience has a net margin of 15.24% compared to Eupraxia Pharmaceuticals' net margin of 0.00%. Niagen Bioscience's return on equity of 23.12% beat Eupraxia Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Niagen Bioscience15.24% 23.12% 15.53% Eupraxia Pharmaceuticals N/A -367.73%-118.31% SummaryNiagen Bioscience beats Eupraxia Pharmaceuticals on 12 of the 15 factors compared between the two stocks. Get Eupraxia Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EPRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EPRX vs. The Competition Export to ExcelMetricEupraxia PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$194.18M$3.13B$5.75B$9.85BDividend YieldN/A2.28%6.67%4.51%P/E Ratio-6.3120.8978.4326.42Price / SalesN/A458.96546.94119.09Price / CashN/A44.5237.0558.92Price / BookN/A9.9310.916.06Net Income-$25.50M-$53.38M$3.29B$266.28M7 Day Performance1.71%0.05%0.01%-0.76%1 Month Performance-0.09%7.08%7.06%3.83%1 Year Performance118.78%11.92%50.09%24.39% Eupraxia Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EPRXEupraxia Pharmaceuticals2.6429 of 5 stars$5.36-0.7%$11.00+105.2%+107.7%$194.18MN/A-6.3129NAGENiagen Bioscience2.1417 of 5 stars$9.67-2.1%$13.42+38.8%N/A$771.21M$116.30M46.05120Analyst UpgradeDAWNDay One Biopharmaceuticals2.337 of 5 stars$7.48+1.1%$25.29+238.0%-44.6%$766.18M$131.16M-7.8760News CoveragePositive NewsVIRVir Biotechnology3.1949 of 5 stars$5.51+10.2%$26.80+386.4%-29.2%$765.45M$74.21M-1.38580News CoverageAnalyst ForecastInsider TradeABUSArbutus Biopharma2.5974 of 5 stars$3.93+2.9%$5.50+39.9%-1.5%$753.38M$15.42M-13.5590News CoveragePositive NewsVALNValneva2.1983 of 5 stars$8.77+1.6%$15.33+74.8%+20.8%$746.24M$183.52M-8.95700Short Interest ↑TNGXTango Therapeutics2.1138 of 5 stars$6.70+0.6%$10.50+56.7%-38.7%$745.44M$42.07M-5.0490News CoveragePositive NewsBGMBGM GroupN/A$7.63+1.7%N/A-8.2%$741.79M$25.10M0.00298Positive NewsGap UpKURAKura Oncology3.8395 of 5 stars$8.43+6.0%$24.10+185.9%-58.3%$731.70M$83.28M-3.73130News CoveragePositive NewsAnalyst ForecastGHRSGH Research2.2408 of 5 stars$14.02+0.6%$32.00+128.2%+42.9%$729.46MN/A-18.9510News CoverageNRIXNurix Therapeutics2.6347 of 5 stars$9.46+3.8%$28.87+205.1%-61.9%$723.22M$54.55M-3.62300News CoveragePositive News Related Companies and Tools Related Companies Niagen Bioscience Competitors Day One Biopharmaceuticals Competitors Vir Biotechnology Competitors Arbutus Biopharma Competitors Valneva Competitors Tango Therapeutics Competitors BGM Group Competitors Kura Oncology Competitors GH Research Competitors Nurix Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EPRX) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredTrump’s national nightmare is hereThe headlines are shocking: Washington has taken a $10 billion stake in one of America’s biggest chipmakers — ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eupraxia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
